{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:17Z","timestamp":1786980137239,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00415-023-11929-2","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T13:02:02Z","timestamp":1692190922000},"page":"6133-6140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["How much refractory is \u2018refractory status epilepticus\u2019? A retrospective study of treatment strategies and clinical outcomes"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-0083","authenticated-orcid":false,"given":"Simona","family":"Lattanzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Meletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"11929_CR1","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","volume":"56","author":"E Trinka","year":"2015","unstructured":"Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S et al (2015) A definition and classification of status epilepticus\u2014report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 56:1515\u20131523","journal-title":"Epilepsia"},{"key":"11929_CR2","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1093\/brain\/aws091","volume":"135","author":"S Shorvon","year":"2012","unstructured":"Shorvon S, Ferlisi M (2012) The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 135:2314\u20132328","journal-title":"Brain"},{"key":"11929_CR3","doi-asserted-by":"publisher","first-page":"e1824","DOI":"10.1212\/WNL.0000000000201099","volume":"99","author":"I Beuchat","year":"2022","unstructured":"Beuchat I, Rosenow F, Kellinghaus C, Trinka E, Unterberger I, R\u00fcegg S, Sutter R, Tilz C, Uzelac Z, Rossetti AO, Strzelczyk A (2022) Refractory Status Epilepticus: Risk Factors and Analysis of Intubation in the Multicenter SENSE Registry. Neurology 99:e1824\u2013e1834","journal-title":"Neurology"},{"key":"11929_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/epi4.12383","volume":"5","author":"N Orlandi","year":"2020","unstructured":"Orlandi N, Giovannini G, Rossi J, Cioclu MC, Meletti S (2020) Clinical outcomes and treatments effectiveness in status epilepticus resolved by antiepileptic drugs: a five-year observational study. Epilepsia Open 5:166\u2013175","journal-title":"Epilepsia Open"},{"key":"11929_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1528-1157.1999.tb02000.x","volume":"40","author":"DH Lowenstein","year":"1999","unstructured":"Lowenstein DH, Bleck T, Macdonald RL (1999) It\u2019s time to revise the definition of status epilepticus. Epilepsia 40:120\u2013122","journal-title":"Epilepsia"},{"key":"11929_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.yebeh.2015.05.007","volume":"49","author":"M Leitinger","year":"2015","unstructured":"Leitinger M, Beniczky S, Rohracher A, Gardella E, Kalss G, Qerama E et al (2015) Salzburg consensus criteria for non-convulsive status epilepticus\u2013approach to clinical application. Epilepsy Behav 49:158\u2013163","journal-title":"Epilepsy Behav"},{"key":"11929_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S1474-4422(16)30137-5","volume":"15","author":"M Leitinger","year":"2016","unstructured":"Leitinger M, Trinka E, Gardella E, Rohracher A, Kalss G, Qerama E et al (2016) Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. Lancet Neurol 15:1054\u20131062","journal-title":"Lancet Neurol"},{"key":"11929_CR8","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1111\/epi.16999","volume":"62","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Giovannini G, Brigo F, Orlandi N, Trinka E, Meletti S (2021) Clinical phenotypes within nonconvulsive status epilepticus. Epilepsia 62:e129\u2013e134","journal-title":"Epilepsia"},{"key":"11929_CR9","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1111\/ene.14891","volume":"28","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Giovannini G, Brigo F, Orlandi N, Trinka E, Meletti S (2021) Status epilepticus with prominent motor symptoms clusters into distinct electroclinical phenotypes. Eur J Neurol 28:2694\u20132699","journal-title":"Eur J Neurol"},{"key":"11929_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.seizure.2017.01.004","volume":"46","author":"G Giovannini","year":"2017","unstructured":"Giovannini G, Monti G, Tondelli M, Marudi A, Valzania F, Leitinger M, Trinka E, Meletti S (2017) Mortality, morbidity and refractoriness prediction in status epilepticus: comparison of STESS and EMSE scores. Seizure 46:31\u201337","journal-title":"Seizure"},{"key":"11929_CR11","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00415-008-0989-1","volume":"255","author":"AO Rossetti","year":"2008","unstructured":"Rossetti AO, Logroscino G, Milligan TA, Michaelides C, Ruffieux C, Bromfield EB (2008) Status epilepticus severity score (STESS): a tool to orient early treatment strategy. J Neurol 255:1561\u20131566","journal-title":"J Neurol"},{"key":"11929_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12028-014-0080-y","volume":"22","author":"M Leitinger","year":"2015","unstructured":"Leitinger M, H\u00f6ller Y, Kalss G, Rohracher A, Novak HF, H\u00f6fler J et al (2015) Epidemiology-based mortality score in status epilepticus (EMSE). Neurocrit Care 22:273\u2013282","journal-title":"Neurocrit Care"},{"key":"11929_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/j.1528-1167.2009.02285.x","volume":"51","author":"E Beghi","year":"2010","unstructured":"Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW et al (2010) Recommendation for a definition of acute symptomatic seizure. Epilepsia 51:671\u2013675","journal-title":"Epilepsia"},{"key":"11929_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.yebeh.2017.03.018","volume":"71","author":"J Redecker","year":"2017","unstructured":"Redecker J, Wittstock M, Rosche J (2017) The efficacy of different kinds of intravenously ap-plied antiepileptic drugs in the treatment of status epilepticus. How can it be deter-mined? Epilepsy Behav 71:35\u20138","journal-title":"Epilepsy Behav"},{"key":"11929_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","volume":"17","author":"GM Brophy","year":"2012","unstructured":"Brophy GM, Bell R, Claassen J et al (2012) Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 17:3\u201323","journal-title":"Neurocrit Care"},{"key":"11929_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","volume":"16","author":"T Glauser","year":"2016","unstructured":"Glauser T, Shinnar S, Gloss D et al (2016) Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr 16:48\u201361","journal-title":"Epilepsy Curr"},{"key":"11929_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109110","volume":"140","author":"S Lattanzi","year":"2023","unstructured":"Lattanzi S, Trinka E, Brigo F, Meletti S (2023) Clinical scores and clusters for prediction of outcomes in status epilepticus. Epilepsy Behav 140:109110","journal-title":"Epilepsy Behav"},{"key":"11929_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/ane.12605","volume":"135","author":"L Delaj","year":"2017","unstructured":"Delaj L, Novy J, Ryvlin P, Marchi NA, Rossetti AO (2017) Refractory and super-refractory status epilepticus in adults: a 9-year cohort study. Acta Neurol Scand 135:92\u201399","journal-title":"Acta Neurol Scand"},{"key":"11929_CR19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40265-021-01502-4","volume":"81","author":"P Bravo","year":"2021","unstructured":"Bravo P, Vaddiparti A, Hirsch LJ (2021) Pharmacotherapy for nonconvulsive seizures and nonconvulsive status epilepticus. Drugs 81:749\u2013770","journal-title":"Drugs"},{"key":"11929_CR20","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1212\/WNL.0000000000012292","volume":"97","author":"P De Stefano","year":"2021","unstructured":"De Stefano P, Baumann SM, Semmlack S, R\u00fcegg S, Marsch S, Seeck M, Sutter R (2021) Safety and efficacy of coma induction following first-line treatment in status epilepticus: a 2-center study. Neurology 97:e564\u2013e576","journal-title":"Neurology"},{"key":"11929_CR21","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S1474-4422(11)70187-9","volume":"10","author":"AO Rossetti","year":"2011","unstructured":"Rossetti AO, Lowenstein DH (2011) Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 10:922\u2013930","journal-title":"Lancet Neurol"},{"key":"11929_CR22","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/epi.13584","volume":"57","author":"LM Kortland","year":"2016","unstructured":"Kortland LM, Alfter A, B\u00e4hr O et al (2016) Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany. Epilepsia 57:2056\u20132066","journal-title":"Epilepsia"},{"key":"11929_CR23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamaneurol.2021.0520","volume":"78","author":"EL Guterman","year":"2021","unstructured":"Guterman EL, Betjemann JP, Aimetti A, Li JW, Wang Z, Yin D, Hulihan J, Lyons T, Miyasato G, Strzelczyk A (2021) Association between treatment progression, disease refractoriness, and burden of illness among hospitalized patients with status epilepticus. JAMA Neurol 78:588\u2013595","journal-title":"JAMA Neurol"},{"key":"11929_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2022.02.012","volume":"97","author":"N Orlandi","year":"2022","unstructured":"Orlandi N, Gozzi A, Giovannini G, Turchi G, Cioclu MC, Vaudano AE, Meletti S (2022) Recurrent status epilepticus: clinical features and recurrence risk in an adult population. Seizure 97:1\u20137","journal-title":"Seizure"},{"key":"11929_CR25","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1097\/CCM.0b013e3182591ff1","volume":"40","author":"RG Kowalski","year":"2012","unstructured":"Kowalski RG, Ziai WC, Rees RN, Werner JK Jr, Kim G, Goodwin H, Geocadin RG (2012) Third-line antiepileptic therapy and outcome in status epilepticus: the impact of vasopressor use and prolonged mechanical ventilation. Crit Care Med 40:2677\u20132684","journal-title":"Crit Care Med"},{"key":"11929_CR26","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1097\/CCM.0000000000000881","volume":"43","author":"NA Marchi","year":"2015","unstructured":"Marchi NA, Novy J, Faouzi M, St\u00e4hli C, Burnand B, Rossetti AO (2015) Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med 43:1003\u20131009","journal-title":"Crit Care Med"},{"key":"11929_CR27","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/epi.17614","volume":"64","author":"P De Stefano","year":"2023","unstructured":"De Stefano P, Baumann SM, Grzonka P, Sarbu OE, De Marchis GM, Hunziker S, R\u00fcegg S, Kleinschmidt A, Quintard H, Marsch S, Seeck M, Sutter R (2023) Early timing of anesthesia in status epilepticus is associated with complete recovery: a 7-year retrospective two-center study. Epilepsia 64:1493\u20131506","journal-title":"Epilepsia"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11929-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11929-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11929-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T09:07:20Z","timestamp":1699434440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11929-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["11929"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11929-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"assertion":[{"value":"10 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Simona Lattanzi has received speaker\u2019s or consultancy fees from Angelini Pharma, Eisai, GW Pharmaceuticals, and UCB Pharma and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, BIAL, Eisai, GW Pharmaceuticals, and Rapport Therapeutics outside the submitted work. Eugen Trinka has received consultancy fees from Arvelle Therapeutics, Argenx, Clexio, Celegene, UCB Pharma, Eisai, Epilog, Bial, Medtronic, Everpharma, Biogen, Takeda, Liva-Nova, Newbridge, Sunovion, GW Pharmaceuticals, and Marinus; speaker fees from Arvelle Therapeutics, Bial, Biogen, B\u00f6hringer Ingelheim, Eisai, Everpharma, GSK, GW Pharmaceuticals, Hikma, Liva-Nova, Newbridge, Novartis, Sanofi, Sandoz and UCB Pharma; research funding (directly, or to his institution) from GSK, Biogen, Eisai, Novartis, Red Bull, Bayer, and UCB Pharma outside the submitted work. Eugen Trinka receives Grants from Austrian Science Fund (FWF), \u00d6sterreichische Nationalbank, and the European Union. Eugen Trinka is the CEO of Neuroconsult Ges.m.b.H. Stefano Meletti received research grant support from the Ministry of Health (MOH) and the non-profit organization Foundation \u201cFondazione Cassa di Risparmio di Modena\u2014FCRM\u201d; has received personal compensation as scientific advisory board member for UCB, Jazz Pharmaceuticals, and EISAI outside the submitted work. The remaining authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}